Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001703
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934</div>

Filed by the Registrant x

Filed by a Party other than the Registrant o

Check the appropriate box:

| o | Preliminary Proxy Statement                                                     |
| o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| o | Definitive Proxy Statement                                                      |
| x | Definitive Additional Materials                                                 |
| o | Soliciting Material Pursuant to §240.14a-12                                     |

<div align='center'>Dynavax Technologies Corporation

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| x | No fee required.                                                                                    |
| o | Fee paid previously with preliminary materials.                                                     |
| o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 14a-6(i)(1) and 0-11. |

This Schedule 14A filing consists of the
following press release distributed by Dynavax Technologies Corporation (the “Company”) to its stockholders in connection
with the Company’s 2025 Annual Meeting of Stockholders. The press release was first used or made available on May 12, 2025.

<div align='center'>Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value

Presentation Underscores Deep Track’s Value Destructive Plan and Inferior Slate of Director Nominees

Urges Stockholders to Vote “FOR”All Four Dynavax Director Nominees on the GOLDProxy Card Today</div>

EMERYVILLE, Calif., May 12, 2025 -- Dynavax Technologies Corporation
(Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing
innovative vaccines, today announced that it has filed an investor presentation with the Securities and Exchange Commission (“SEC”)
in connection with its 2025 Annual Meeting of Stockholders to be held on June 11, 2025. Stockholders of record as of April 14,